An observational study in Hypertension and Diabetes, sponsored by National Human Genome Research Institute (NHGRI). Recruiting at 5 sites in 2 countries. Open to participants aged 18 Years to 120 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by National Human Genome Research Institute (NHGRI) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Hypertension with a site in Nigeria — 11 open to participants now, 14 under way, none of them phase 3. Hypertension · Nigeria.
Among the 31 studies in Hypertension with a site in Nigeria, this one is the 2nd largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2009, is one of 10 observational ones, and was the 2nd registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →11 of the 31 studies in Hypertension with a site in Nigeria are open now. Recruiting first, the newest first:
Washington University School of Medicine · Sites in Nigeria
Ages 18+
Johns Hopkins University · Sites in Nigeria, United States, Ghana
Ages 18–70
Washington University School of Medicine · Sites in Nigeria
Women only
University of Leeds · Sites in Nigeria
Ages 18–70 · Healthy volunteers
AstraZeneca · Sites in Nigeria, Brazil, Chile and 17 more countries
Ages 18+
A study can be open while its sites in Nigeria have not opened yet or have stopped. Only those recruiting at a site in Nigeria →
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years to 120 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 352 across 1,166 observational studies indexed under Hypertension.
Median enrollment 830 across the 21 interventional studies, 2,915 across the 10 observational. Of the 14 that completed or were terminated, 3 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 31 have an industry lead sponsor. The 10 most frequent:
National Human Genome Research Institute (NHGRI) is the lead sponsor of 203 studies on the registry; 33 are open to participants now.
National Human Genome Research Institute (NHGRI) has 4 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
4 of the studies in Hypertension with a site in Nigeria that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT06659900Oregon Health and Science UniversityCommunity Vital Signs (CVS): An Integrated Community-Based Approach to Identify Undiagnosed Hypertension in Nigeria | 2027-06 |
| NCT06773299Washington University School of MedicineEnhancing Intergenerational Health in Nigeria: Peripartum as Critical Life Stage for Cardiovascular Health | 2027-10 |
| NCT07386535Washington University School of MedicineInnovative Tools to Expand Music-Inspired Strategies for Blood Pressure and Stroke Prevention | 2027-10-26 |
Add all 4 to your calendar (.ics) → With an account.
Among the 31 studies in Hypertension with a site in Nigeria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background:
Objectives:
Eligibility:
Design:
Study Description:
This protocol is designed to study the genetic basis of Type 2 Diabetes (T2D) and related conditions in Africa.
Objectives:
Primary Objective: To conduct genetic association studies of T2D, T2D complications, and related traits in Africans of diverse ethnic groups
Secondary Objectives:
Endpoints:
Primary Endpoint: T2D
Secondary Endpoints: T2D Complications, Hypertension, Obesity, Dyslipidemia, Metabolic Syndrome, Chronic Kidney Disease, and other cardiometabolic traits
Patients with confirmed T2D who are newly diagnosed or on treatment and those without T2D (ethnically matched) in Ibadan, Nigeria
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
As our primary interest is in T2D, it is important to exclude individuals who may have diabetes of another etiology. Elevated blood glucose in individuals 25 years old or younger is unlikely (in West Africa) to result from T2D and may reflect Type 1 Diabetes. Therefore, only individuals older than 25 years will be included in this study.
We are seeking to enroll persons without T2D or with previously or newly diagnosed T2D. Previously diagnosed cases will be determined by self-report of being treated with oral medication or insulin. Newly diagnosed cases will be determined by fasting blood glucose value >= 126 mg/dl on more than one occasion. Individuals who have elevated blood glucose during their initial reading will be asked to return to the study site for a second test. If this test also has a fasting blood glucose value >= 126 mg/dl, then they will be considered a new case. The control group will be individuals with no report of T2D diagnosis and fasting plasma glucose (FPG)\< 126 mg/dl.
Only unrelated individuals will be included in this phase of the study to avoid confounding genetic association studies by relatedness in the study population.
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this study:
Control subjects are nondiabetics ethnically matched to patients
Patients with confirmed T2D who are newly diagnosed or on treatment in Ibadan, Nigeria
I
In a subset of participants, to investigate the relationship between diets, gut microbiota, and T2D/related traits.
Time frame: ongoing
H
To investigate whether hemoglobin A1c (HbA1c) as an indicator of blood glucose control over time is reliable in the presence of the sickle cell trait (HbS), a common hemoglobinopathy in West Africa. The association between HbA1c repeated measures and changes in T2D-related traits over time will be evaluated. We will also evaluate if there is a systematic difference (bias) in the estimation of A1c in carriers of the sickle trait and non-carriers in persons with and without diabetes.
Time frame: ongoing
G
g- In a subset of participants, to investigate key tissues in the pathophysiology of T2D, we will study differences in the gene expression of skeletal muscle and adipose tissue in lean and obese individuals with and without T2D (n=100, Biopsy Substudy).
Time frame: ongoing
F
f- To conduct population genetic analyses to describe population history and to develop statistical techniques appropriate for genetic analysis of African ancestry individuals.
Time frame: ongoing
E
e-To describe these individuals epidemiologically in terms of metabolic traits and the prevalence of relevant conditions, as, for some traits, this may be the first large-scale epidemiological, population-based study of Africans with the appropriate data for such description.
Time frame: ongoing
D
d- To conduct trans-ethnic fine mapping to determine whether the reduced LD across the genome in African ancestry individuals can refine the region of interest around genetic associations discovered in populations of non-African ancestry. To conduct candidate gene resequencing, Whole Genome Sequencing (WGS), or Whole Exome Sequencing (WES), as funding allows, in participants with metabolic profiles of interest. For instance, individuals will be selected who have extreme values for serum lipids for WES. Variants identified by this resequencing will be genotyped in the larger study population for association analysis.
Time frame: ongoing
C
c- To develop a large-scale genetic epidemiological resource for the replication of findings in other studies of related traits in African ancestry and non-African ancestry individuals.
Time frame: ongoing
B
b- To investigate the contribution of gene x environment interactions in T2D risk and in influencing related traits. These investigations may be conducted on either a hypothesis-driven, locus-specific manner or agnostically, i.e. genome-wide. Environmental variants to be considered include lifestyle factors (e.g. diet, measured by food frequency questionnaires (FFQ), socioeconomic measures, and medications taken.
Time frame: ongoing
A
a- To conduct genetic association studies of T2D and related traits (including blood pressure, serum lipids, blood glucose, adiposity) in West Africans of diverse ethnic groups. Approaches will include genome-wide association studies (including exome chip data) and candidate gene/loci association analyses.
Time frame: ongoing
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Plan to share: No — Extensive review of the consents related to this protocol by the NHGRI IRB was conducted and it was determined that because the initial consent process did not address sharing of participants' data and the related risks and the carefully established rapport and trust with African populations and collaborators, it would not be appropriate to share participant's data. A memorandum to this effect can be provided, if necessary. We will continue to be open to making the data available through collaboration, a use of the data that was described in initial consent forms.
No publications or documents are linked to this record.
Started Feb 2009 (actual).
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Human Genome Research Institute (NHGRI) →